← All candidates
53 insider filings on record.
57 filings on record.
LGVNLongeveron Inc.
NasdaqCM · Healthcare · $21.97M
$6.86
-0.87% · Sep 15
53 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what LGVN ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$21.97M
Float
2.4M
78% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
18.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Locklear Lisa
Bought 11,766 sh on Aug 11 — held direct, 4.7% of their stake.
0 of 1 position beat the S&P
Director
Baluch Khoso
Bought 11,766 sh on Aug 11 — held direct, 22% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
48 more transactions on Pro →Context
Wall St
$71.50 avg target
+942.3% vs today · 3 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$1.90 act+$0.00
Q1 '26−$1.90 act−$0.17
Q4 '25−$2.20 act+$1.47
Q3 '25−$3.90 act−$1.33
The file stays open
57 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice